Terms ending in 2028
Every in-force patent on Oncotherapy Science, Inc.'s record whose computed term ends in 2028, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 9,067,973 | Peptide Vaccines for Cancers Expressing Tumor-Associated Antigens In force · Medium confidence | Oncotherapy Science, Inc. | In force | Medium confidence | |
| US 9,284,349 | Peptide Vaccines for Cancers Expressing Tumor-Associated Antigens In force · High confidence | OncoTherapy Science, Inc. | In force | High confidence | |
| US 8,221,751 | Tumor-Targeting Monoclonal Antibodies to FZD10 and Uses Thereof In force · High confidence | Oncotherapy Science, Inc. | In force | High confidence | |
| US 9,073,968 | FOXM1 Peptide and Medicinal Agent Comprising the Same In force · High confidence | Oncotherapy Science, Inc. | In force | High confidence | |
| US 9,415,096 | FOXM1 Peptide and Medicinal Agent Comprising the Same In force · High confidence | Oncotherapy Science, Inc. | In force | High confidence | |
| US 8,383,590 | Peptide Vaccines for Cancers Expressing Tumor-Associated Antigens In force · High confidence | Oncotherapy Science, Inc. | In force | High confidence | |
| US 8,557,955 | Peptide Vaccines for Cancers Expressing MPHOSPH1 or DEPDC1 Polypeptides In force · High confidence | Oncotherapy Science, Inc. | In force | High confidence |
7 of 7 patents shown. Soonest term end first, then patent number.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.